NCT06127108 - Clinical Evaluation of the Panbio™ COVID-19/Flu A&B Panel | Biotech Hunter

Enrollment

447

Participants

Timeline

Start Date

November 14, 2023

Primary Completion Date

February 2, 2024

Study Completion Date

February 2, 2024

Conditions

COVID-19Influenza AInfluenza B

Interventions

DIAGNOSTIC_TEST

Panbio™

The Panbio™ COVID-19/Flu A\&B Panel is a visual lateral flow in vitro immunoassay for the qualitative detection of the nucleocapsid protein antigen to SARS-CoV-2, Influenza A, and Influenza B in anterior nasal swab samples from individuals with symptoms and suspected of COVID-19 or Flu infection by their healthcare provider.

Trial Locations (1)

22180

Advanced Pediatrics, Vienna

All Listed Sponsors

lead

Abbott Rapid Dx

INDUSTRY